<DOC>
	<DOC>NCT01244828</DOC>
	<brief_summary>This is a multi-site, open-label fixed-flexible dose long-term study of asenapine in participants with schizophrenia. Participants in this study consist of schizophrenia with residual subtype or receiving high dose/multiple antipsychotic drugs, treatment refractory, or elderly participants with schizophrenia. The treatment period is up to 52 weeks.</brief_summary>
	<brief_title>Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Minimum age of 20 years Participants who meet at least one of the following: current diagnosis of schizophrenia of residual subtype received treatment with 3 or more antipsychotic drugs treatmentrefractory participants with schizophrenia 65 years old and over with positive schizophrenia symptoms with score of 3 (mild) or more in 1 or more items in the positive subscale of the Positive and Negative Syndrome Scale (PANSS) at the baseline Participants who have a Clinical Global ImpressionsSeverity (CGIS) score of at least 4 (moderately ill) at the baseline Uncontrolled, unstable clinically significant medical condition Clinically significant abnormal laboratory, vital sign, physical examination, or electrocardiogram (ECG) findings at Screening Positive pregnancy test at Screening, or the intention to become pregnant during the course of the study Seizure disorder beyond childhood (12 years old or younger) History of neuroleptic malignant syndrome Allergy or sensitivity to drugs such as psychotropics and antipsychotics Known history of or currently treated for narrow angle glaucoma Parkinson's disease Diagnosis of schizoaffective disorder; schizophreniform disorder Concurrent psychiatric disorder other than schizophrenia coded on Axis I; a primary diagnosis other than schizophrenia Diagnosis of borderline personality disorder Diagnosis of mental retardation or organic brain disorder Current (past 6 months) substance abuse or dependence according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSMIV) criteria (excluding nicotine) Positive drug/alcohol tests at the Screening visit Imminent risk of selfharm or harm to others, in the Investigator's opinion Substance induced psychotic disorder or a behavioral disturbance thought to be due to substance abuse Currently under involuntary inpatient confinement Use of a nonapproved drug in Japan within 12 weeks prior to informed consent Previously treated in an asenapine study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>